Does format matter? Comparing the efficacy of online, hybrid, and onsite Mindfulness-Based Stress Reduction (MBSR) on the well-being benefits for postgraduate students.

Start Date09 Mar 2025

Sponsor / Collaborator

Xian Jiaotong-Liverpool University

NCT06820619

/ RecruitingNot ApplicableIIT

Efficacy of Mindfulness-based Training for Teachers and Young Children for Social Emotional and Ethical Development (SEED)-Randomized Controlled Trial

The objectives of the present study are to (1) evaluate the effectiveness of implementing teachers' training on mindfulness and developing their competency in delivering the Social, Emotional, and Ethical Development (SEED) curriculum to preschool children and (2) evaluate the effectiveness of the SEED curriculum at kindergartens in improving children's well-being and related outcomes. Randomized controlled trials will be conducted to investigate the effectiveness of SEED teacher training and the SEED Curriculum. A minimum of four kindergartens will be recruited to participate in the study. Half of the kindergartens, teachers, and children will receive the training and SEED curriculum, while the other half will be assigned to the waitlist control condition. Upon informed consent from the school principals and parents, teachers will receive mindfulness training and complete pre- and post-training assessments, and one-month follow-up assessments. Teachers will be taught 8 mindfulness exercises to be integrated into daily teaching and students in the intervention group will receive a 30-minute lesson of SEED curriculum per week, 12 weeks in duration, led by the Bodhi Love Foundation SEED trainers. Parents and students will complete assessments before intervention and after intervention(in the 12th week).

Start Date02 Dec 2024

Sponsor / Collaborator

The Chinese University of Hong Kong

[+1]

NCT06122844

/ CompletedNot ApplicableIIT

Feasibility of Mindfulness-based Training for Teachers and Young Children for Social Emotional and Ethical Development (SEED)

The objectives of the present study are to (1) evaluate the feasibility and effectiveness in implementing teachers' training on mindfulness and developing their competency in delivering the Social, Emotional, and Ethical Development (SEED) curriculum to preschool children and (2) pilot the SEED curriculum at kindergartens to assess its effectiveness.
To investigate the feasibility of SEED teacher training and the SEED Curriculum, randomized controlled trials will be conducted. A minimum of two kindergartens will be recruited to participate in the study. Half of the kindergartens, teachers, and children will receive the training and SEED curriculum, while the other half will be assigned to the waitlist control condition. Upon informed consent from the school principals and parents, parents, teachers, and children will complete pre- and post-assessments, additional follow-up assessments will be conducted in intervention group. Focus group interviews will be conducted with teachers to understand their acceptability, demand, practicality, integration, and efficacy of the teacher training at post-teacher training and delivery of the SEED curriculum for children at post-intervention. Another focus group interviews will be conducted with SEED trainers to get information about teachers' participation rate in the training session.

Start Date16 Sep 2023

Sponsor / Collaborator

The Chinese University of Hong Kong

[+1]

100 Clinical Results associated with Xian Jiaotong-Liverpool University

0 Patents (Medical) associated with Xian Jiaotong-Liverpool University

1,610

Literatures (Medical) associated with Xian Jiaotong-Liverpool University

01 Apr 2026·BIOMATERIALS

Development of a biodegradable smooth-surface microcarrier for retinal pigment epithelial cell expansion and maturation

Article

Author: Su, Xinyi ; Loh, Xian Jun ; Liu, Hang ; Li, Zibiao ; Al-Mubaarak, Abdurrahmaan ; Wong, Daniel Soo Lin ; Parikh, Bhav Harshad ; Bhargava, Mayuri ; Li, Jian ; Liu, Zengping ; Yang, Binxia

The retinal pigment epithelium (RPE) is essential for the health and function of the retina and, more specifically, the photoreceptors. Hence, the dysfunction of RPE leads to various retinal degeneration diseases. The rising prevalence of these disorders highlights the need for effective, large-scale cell-based therapies, particularly those utilizing stem cell-derived RPE cells. This study presents the development of a biodegradable, smooth surface microcarrier designed to facilitate the expansion and maturation of RPE cells derived from induced pluripotent stem cells (iPSCs). Using a three-dimensional (3D) culture system with polycaprolactone (PCL) porous microcarriers, we demonstrate that RPE cells exhibit comparable adhesion and growth on microcarriers as they do on traditional two-dimensional (2D) culture plates. The microcarrier system facilitates efficient maturation and yields higher quantities of functional RPE cells, highlighting its potential for large-scale production to meet both clinical demands and in vitro large-scale screening studies. Moreover, RPE cells cultured on this microcarrier can be directly frozen and recovered, maintaining their phenotypic and functional integrity upon thawing. This research showcases the scalability and practicality of RPE cell production, providing a robust solution for the storage and delivery of RPE cells. While our results establish the feasibility of direct cryopreservation and recovery of monolayer RPE cells on microcarriers, the designation of a 'ready-to-use' product format is preliminary and will require expanded assessment of long-term functionality, safety, and direct translational outcomes in future studies.

01 Apr 2026·NEURAL NETWORKS

ERANet: Edge replacement augmentation for semi-supervised meniscus segmentation with prototype consistency alignment and conditional self-training

Article

Author: Griffith, James F ; Yao, Yongcheng ; Li, Siyue ; Chen, Weitian ; Hong, Jin ; Zhong, Junru ; Xiao, Fan ; Ho, Ki-Wai Kevin ; Zhao, Shutian ; Wang, Shuihua ; Zhang, Yudong ; Ong, Tim-Yun Michael

The meniscus, a fibrocartilaginous structure within the knee joint, plays an essential role in joint stability and the prevention of knee osteoarthritis (OA). Accurate segmentation of the meniscus from magnetic resonance imaging (MRI) is crucial for early diagnosis and monitoring of OA progression. However, manual segmentation is labor-intensive, while automatic approaches face challenges due to variability in meniscal morphology, partial volume effects, and low tissue contrast. To address these challenges, we propose ERANet, a semi-supervised framework that effectively leverages both labeled and unlabeled data through anatomically guided augmentation, consistency regularization, and iterative pseudo label refinement. Central to ERANet is edge replacement augmentation (ERA), a meniscus-specific augmentation strategy that introduces plausible morphological perturbations by modifying peripheral meniscal regions with context-aware background information. ERA is tailored to address the unique anatomical variability of meniscal structures. Alongside ERA, ERANet incorporates two generalizable learning modules: prototype consistency alignment (PCA), which enforces feature compactness via prototype-guided regularization, and conditional self-training (CST), which selectively incorporates reliable pseudo labels based on their temporal stability. The synergistic interaction among these modules enables ERANet to handle small, low-contrast anatomical structures with limited supervision. We validated ERANet on 3D DESS and 3D FSE MRI sequences, demonstrating superior segmentation performance compared to state-of-the-art semi-supervised methods. ERANet maintains high accuracy even with minimal labeled data, and extensive ablation studies confirm the individual and combined benefits of ERA, PCA, and CST. Our results suggest that ERANet offers a robust and scalable solution for meniscus segmentation. Code is available at https://github.com/SiYueLi-MRIandAI/ERANet.

01 Mar 2026·PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Gender-specific perspectives in schizophrenia: Recent advances and future directions

Review

Author: Ashraf, Ghulam Md ; Alshanberi, Asim Muhammad ; Khan, Faez Iqbal ; Ansari, Shakeel Ahmed ; Saboor, Muhammad ; Alam, Mohammad Zubair

Schizophrenia is a severe psychiatric disorder that occurs more frequently in males than in females. Males typically show symptoms earlier in life, while females tend to develop symptoms later, with a peak after menopause. Men have a higher incidence rate, but the overall prevalence is similar between genders. Several studies have identified potential biopsychosocial reasons for these differences. The "estrogen hypothesis," which suggests a neuroprotective effect of estrogen in women, has gained support despite limited evidence for genetic and neurodevelopmental factors. Differences based on symptoms have also been connected to distinct psychological vulnerabilities in men and women. Emerging research indicates that genetic and neurodevelopmental factors may play a less significant role in female schizophrenia compared to males. In this context, the estrogen hypothesis, which proposes a neuroprotective role for estrogen, has gained attention as a possible explanation for sex-related differences in disease expression and progression. These gender-based differences in schizophrenia might reflect variations in symptom profiles that are influenced by underlying psychological and neurobiological vulnerabilities unique to each sex. A thorough investigation of these gender-specific mechanisms is necessary to deepen understanding of the causes and to develop more personalized and effective treatments.

News (Medical) associated with Xian Jiaotong-Liverpool University

08 Nov 2022

·www.prnewswire.com

XJTLU and University of Liverpool to inaugurate Joint Centre for Pharmacology and Therapeutics

SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- On 11 November, Xi'an Jiaotong-Liverpool University (XJTLU) and the University of Liverpool will inaugurate their Joint Centre for Pharmacology and Therapeutics at an online/onsite event in Suzhou, China. The Joint Centre, a Sino-UK collaborative venture, will engage top scientists from both countries to enhance research on disease mechanisms and develop novel drugs for the treatment of modern-day diseases. Continue Reading Xi'an Jiaotong-Liverpool University (XJTLU) researchers conduct world-class biopharmaceutical research at the University's Suzhou Industrial Park (SIP) campus. XJTLU and the University of Liverpool will inaugurate their Joint Centre for Pharmacology and Therapeutics on 11 November. Top scientists from both universities will work to enhance research on disease mechanisms and develop novel drugs to treat modern-day diseases. As a global research hub for interdisciplinary and innovative research, the Joint Centre will offer a unique platform for knowledge exchange and talent cultivation between academic laboratories and their industrial and clinical partners in basic and clinical research on drug safety science, immuno-pharmacology, precision medicine, nanomedicine and regulatory science. Members of the Joint Centre include senior researchers from XJTLU; the Department of Pharmacology and Therapeutics from the University of Liverpool, an established world leader in pharmacology and toxicology research; Hengrui Pharmaceutical Co., Ltd (Shanghai), a pharmaceutical giant in China; and Suzhou Guangji Psychiatric Hospital. The Joint Centre's research and development (R&D) activities are expected to benefit both Suzhou – which boasts over 400 high-tech biopharmaceutical startups in its BioBAY industrial park and aims to be the "Pharmacy Valley of China" – and the Liverpool City Region. "The combination of expertise, skills, facilities and resources from XJTLU and the University of Liverpool will offer a great opportunity for both universities to make significant impacts in the sector and foster new research areas," says XJTLU's Dr Meng Huee Lee, Co-director of the Joint Centre. The Joint Centre will harness state-of-the-art equipment and facilities in pharmaceutical sciences, molecular biology, chemistry, and environmental sciences along with activities funded by the government, the private sector and the pharmaceutical industry. XJTLU PhD students, who are jointly supervised by XJTLU and the University of Liverpool, will benefit from the strengthened R&D ties. Furthermore, the Joint Centre's close link with local pharmaceutical companies will ensure a steady supply of researchers meeting pharmaceutical industry demands of today and tomorrow. "With our partners at XJTLU, through teaching and research, we will nurture a talent pipeline of research leaders and exciting international collaborations and ventures," says University of Liverpool Professor Christopher Goldring, Co-director of the Joint Centre. The inauguration of the Joint Centre is part of XJTLU Wisdom Lake Academy of Pharmacy's second-year anniversary celebration. SOURCE Xi'an Jiaotong-Liverpool University

Collaborate

100 Deals associated with Xian Jiaotong-Liverpool University

100 Translational Medicine associated with Xian Jiaotong-Liverpool University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

T1PrαTACE ( TIMP1 )	Squamous Cell Carcinoma of Head and Neck More	Preclinical
acRNA-CAR-NK(Jiangsu Yiming Biotechnology)	Neoplasms More	Preclinical
TIMP-CAR-NK(Jiangsu Yiming Biotechnology)	Neoplasms More	Preclinical
CN119751501 Patent Mining	Nervous System Diseases More	Discovery
CN116270704 ( SOD1 )Patent Mining	Adnexal Diseases More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis